I’m a fundamental, valuation-driven investor with a strong focus on identifying businesses that have the potential to scale over time and unlock massive terminal value. My investment approach centers around understanding the core economics of a business—its competitive moat, unit economics, reinvestment runway, and management quality—and how those factors translate into long-term free cash flow generation and shareholder value creation. I focus on fundamental research, and I tend to focus on sectors with st ...

RT Easy (@EasyEatsBodega)Idk brosMultiple publicly traded companies have the need for eth price to go up nowLike their entire end goal is making that price go up for shareholder valueAnd rumor is many more are comingOn top of that, one of them has more eth on hand than the foundationIt kinda feels like eth will get the infinite institutional bid && ultimately alts will run on the back of thatRisk curve expands but eth leader of alt szn happening now n for the future. ...

Idk brosMultiple publicly traded companies have the need for eth price to go up nowLike their entire end goal is making that price go up for shareholder valueAnd rumor is many more are comingOn top of that, one of them has more eth on hand than the foundationIt kinda feels like eth will get the infinite institutional bid && ultimately alts will run on the back of thatRisk curve expands but eth leader of alt szn happening now n for the future. ...

ATLANTA, July 17, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Capricor’s four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. If you purchased shares of Capricor between October 9, 2024 and July 10, 2025, and experienced ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Krispy Kreme, Inc. due to a class action lawsuit alleging breaches of fiduciary duties by the board of directors during a specified class period [1][2]. Group 1: Class Action Lawsuit Details - The class action lawsuit claims that Krispy Kreme made false or misleading statements regarding the demand for its products at McDonald's locations, which significantly declined after the initial marketing launch [2]. - It is alleged that the declining demand at McDonald's contributed to a decrease in average sales per door per week and that the partnership with McDonald's was not profitable, posing risks to the continuation of this partnership [2]. - The lawsuit also states that Krispy Kreme would pause its expansion into new McDonald's locations due to these issues [2]. Group 2: Financial Performance - On May 8, 2025, Krispy Kreme reported its first quarter 2025 financial results, revealing net revenue of $375.2 million, a decline of 15.3% compared to the previous year [3]. - The company also reported a net loss of $33.4 million, a significant increase from the prior year's net loss of $6.7 million [3]. - Following the release of these financial results, Krispy Kreme announced it would reassess its deployment schedule with McDonald's and withdrew its prior full-year outlook, citing uncertainty around the McDonald's deployment schedule [3]. - The announcement led to a nearly 25% drop in Krispy Kreme's share price [3].

For reference on said meetinghttps://t.co/T4FhgWzVwAmakesy 🟢 (@0xMakesy):Just checked out the YHC bylaws- per a November 2024 amendment, special meetings can be called by owners of 33 1/3% of voting shares (less than usual 50% threshold)- directors can be removed with a 2/3 vote of shareholdersCall the meeting with haste @rleshner @matt_levine https://t.co/NnB9OUMsKA ...

Financial Activities - Häagen-Dazs ice cream maker Froneri is finalizing a debt deal [1] - The debt deal is to fund one of the largest shareholder payouts on record [1]

Core Viewpoint - SEGG Media Corporation, formerly known as Lottery.com Inc., is undergoing a corporate transition that includes a CUSIP number change to enhance shareholder protection and market transparency while addressing concerns about illicit trading activities [1][2][3]. Group 1: Corporate Transition - The company has completed its corporate rebrand and is now trading under the ticker symbol 'SEGG' [2]. - The CUSIP change is part of a broader strategy to modernize SEGG's market identity and improve protections against negative trading practices, particularly short selling [2][3]. Group 2: Regulatory Actions - SEGG Media is collaborating with outside counsel to investigate potential illegal market activities, including naked short selling, to protect shareholder interests [3]. - The CUSIP change is seen as a protective measure in response to observed shorting patterns and potentially unlawful activities targeting the company's stock [3]. Group 3: Company Commitment - SEGG Media is committed to safeguarding shareholder value and pursuing an aggressive roadmap focused on acquisitions, innovation, and global expansion in the sports, entertainment, and gaming sectors [3]. Group 4: Company Overview - SEGG Media operates a portfolio of digital assets, including Sports.com and Lottery.com, and is focused on immersive fan engagement, ethical gaming, and AI-driven live experiences [5].

Recent Form 8-K Filing Indicates that Tisch and Bielli Led Board Has Learned Nothing about Disclosure and Transparency from the Company's Recent Proxy FightUrges Tejon Ranch's Board of Directors to Disclose Full Details Surrounding Brett Brown's Departure  Calls on Tejon's Independent Directors to Follow the Recommendations of Leading Proxy Advisory Firms in Adopting PFS Trusts Shareholder Proposal that Received 49.3% of the Vote PALO ALTO, Calif., July 16, 2025 /PRNewswire/ -- Glenbrook Capital Management ...

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations - The lawsuit claims that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole as a treatment for SCA [2]. - It is also alleged that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The revelations from the lawsuit are expected to have a significant negative impact on Biohaven's business and financial condition [2]. Group 3: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3].